Patents Examined by Kahsay Habte
  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11629136
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: April 18, 2023
    Assignee: NURA BIO, INC.
    Inventors: Rao Kolluri, Christopher Michael Tegley, Liusheng Zhu, Sean Pomeroy Brown, Charles Howard Reynolds, Andrew Stewart Tasker, Cheryl A. Grice
  • Compounds active towards nuclear receptors
    Patent number: 11613532
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: March 28, 2023
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Luigi Piero Stasi
  • Small molecule activators of Tie-2
    Patent number: 11613534
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for vascular disorders that can include, for example, retinopathies, ocular edema, and ocular neovascularization.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: March 28, 2023
    Assignee: EyePoint Pharmaceuticals, Inc.
    Inventor: John M. Janusz
  • PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
    Patent number: 11608342
    Abstract: The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: March 21, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Kate Wen, Yazhou Wang
  • Somatostatin modulators and uses thereof
    Patent number: 11608335
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: March 21, 2023
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Jian Zhao, Shimiao Wang, Yunfei Zhu
  • Anti-SARS CoV-2 inhibitors by dual viral-host targeting
    Patent number: 11608331
    Abstract: The present invention discloses novel SARS-CoV-2 inhibitors for therapeutic formulations and methods for treating SARS-CoV-2 infections. The compounds exhibit unique pharmacophoric features including conformational flexibility and spatial orientation within the binding sites of the targeted proteases. The present invention also discloses methods for treating SARS-CoV-2 infections, comprising administering to the subject in need thereof a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutical excipients.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: March 21, 2023
    Assignee: UNIVERSITY OF SHARJAH
    Inventors: Sameh S. M. Soliman, Bahgat Fayed, Rania Hamdy, Ahmed M. Almehdi
  • 5-HT2C receptor agonists and compositions and methods of use
    Patent number: 11608339
    Abstract: The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: March 21, 2023
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Graeme Semple, Albert S. Ren, Thomas O. Schrader, Michelle Kasem, Xiuwen Zhu
  • Acyl hydrazone derivative compounds for treating disease
    Patent number: 11603364
    Abstract: The present invention relates to compounds that have zinc and/or iron ionophore activity and their use in treating diseases that are modulated by reducing zinc and/or iron.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: March 14, 2023
    Assignee: Alterity Therapeutics Limited
    Inventors: Silas Bond, Penelope Jane Huggins, Jack Gordon Parsons
  • Benzothiadiazepine compounds and their use as bile acid modulators
    Patent number: 11603359
    Abstract: The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: March 14, 2023
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Jan Mattsson, Ingemar Starke, Santosh S. Kulkarni
  • Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 11597721
    Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 7, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zili Xiao, Michael G. Yang, Chunjian C. Liu, Trevor C. Sherwood, John L. Gilmore, David S. Weinstein
  • Processes for preparing oxathiazin-like compounds
    Patent number: 11591302
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: February 28, 2023
    Assignee: GEISTLICH PHARM A AG
    Inventors: Rolf W. Pfirrmann, Hanns Moehler, Thomas Mueller
  • Certain chemical compositions and methods of use thereof
    Patent number: 11591322
    Abstract: The present disclosure provides CDK9 inhibitors. Also provided are methods of treating a disease or a disorder comprising administering to a subject in need of treatment one of the CDK9 inhibitors disclosed herein. In some embodiments, the disease or disorder to be treated is cancer. In some embodiments, the disease or disorder is liver cancer.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: February 28, 2023
    Assignee: Algen Biotechnologies, Inc.
    Inventors: Andrei W. Konradi, Chun-Hao Huang, Ko-Chuan Lee
  • GLP-1R agonists and uses thereof
    Patent number: 11591321
    Abstract: The present disclosure provides compounds of Formula (III) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: February 28, 2023
    Assignee: QILU REGOR THERAPEUTICS INC.
    Inventors: Wenge Zhong, Wei Guo
  • PARP1 inhibitors and uses thereof
    Patent number: 11591331
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: February 28, 2023
    Assignee: XINTHERA, INC.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 11590139
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: February 28, 2023
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Oxazolidinone antibiotic compounds and process of preparation
    Patent number: 11590142
    Abstract: Compounds of Formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments are provided. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. Methods for the synthesis and characterization of the aforementioned substances are also provided.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: February 28, 2023
    Assignee: BUGWORKS RESEARCH, INC.
    Inventors: Shahul Hameed Peer Mohamed, Nagakumar Bharatham, Nainesh Katagihallimath, Sreevalli Sharma, Radha Nandishaiah, Vasanthi Ramachandran
  • Fluoroalkyl-oxadiazoles and uses thereof
    Patent number: 11578066
    Abstract: Provided herein are compounds identified as inhibitors of HDAC6 activity having the formula: or a pharmaceutically acceptable salt thereof, that can be used to treat various diseases and disorders.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: February 14, 2023
    Assignee: Tenaya Therapeutics, Inc.
    Inventors: Snahel Patel, Mohammad A. Mandegar, David Sperandio, Julio Medina, Ulhas Bhatt, Alok Nerurkar, Tien Widjaja
  • Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV
    Patent number: 11571409
    Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: February 7, 2023
    Assignee: New York Blood Center, Inc.
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11566022
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders, including hemoglobinopathies, sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: January 31, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Dales, John Ryan Kerrigan, Philip Lam, Hasnain Ahmed Malik, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Ting
  • Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
    Patent number: 11566015
    Abstract: Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: January 31, 2023
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Sangdon Han, Yunfei Zhu, Sun Hee Kim, Jian Zhao, Shimiao Wang